Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer

• Published in: Postȩpy higieny i medycyny doświadczalnej Vol. 69; pp. 586 - 597
• Main Authors: Dębska-Szmich, Sylwia, Kusińska, Renata, Czernek, Urszula, Szydłowska-Pazera, Katarzyna, Habib-Lisik, Maja, Piekarski, Janusz H, Olas, Elżbieta, Kulig, Andrzej, Ułańska, Małgorzata, Kalinka-Warzocha, Ewa, Potemski, Piotr
• Format: Journal Article
• Language: English
• Published: Poland 05.05.2015
• Subjects: Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Female; Gene Expression; Humans; Immunohistochemistry; Middle Aged; Phosphorylation; Prognosis; PTEN Phosphohydrolase - genetics; Receptor, ErbB-2 - drug effects; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Receptor, ErbB-3 - genetics; Trastuzumab - therapeutic use; Treatment Outcome
• ISSN: 1732-2693
• DOI: 10.5604/17322693.1151339

HER2 overexpression is an unfavorable prognostic factor in patients with breast cancer, but it is also a target for the monoclonal antibody trastuzumab, which is effective in adjuvant and palliative settings. HER2 positivity is an inclusion criterion for immunotherapy, but it is not a positive predictive factor, and only half of patients benefit from the treatment. The aim of this study was to evaluate the prognostic and predictive value of HER3, PTEN and phosphorylated HER2 (p-HER2) expression in primary breast tumors of patients treated with trastuzumab in an adjuvant or palliative regimen. Immunohistochemical (IHC) analysis with 3 antibodies specific to the proteins was performed in tumor specimens obtained from 81 HER2-positive patients treated with trastuzumab. HER3 overexpression was present in 55.6% of the examined tumors, and PTEN or pHER2 positivity was present in 32.0% and 34.6% of them, respectively. HER3 overexpression and PTEN positivity correlated with larger tumor size (p=0.016 and p=0.008, respectively). p-HER2 positivity correlated with more advanced clinical stage of the disease (p=0.032). There was no correlation between the proteins' expression and survival for 31 patients treated with trastuzumab in the palliative regimen. HER3 overexpression, PTEN positivity and p-HER2 positivity in tumor cells of HER2-positive patients correlate with more advanced clinical stage of breast cancer. Expression of these proteins does not predict outcome of trastuzumab treatment.